Hello Heart

Hello Heart Competitive Intelligence & Landscape

helloheart.com ·

Overview

Hello Heart Overview

Hello Heart is a healthcare technology company dedicated to transforming cardiovascular health management through innovative digital solutions. Founded in 2013 in Tel Aviv, Israel, by Maayan Gonnen-Cohen, the company specializes in providing a comprehensive digital health platform that includes an app and connected heart monitors designed to help individuals track and manage their heart health effectively (tracxn, helloheart).

The company's core products are its digital coaching app and connected devices, which focus exclusively on cardiovascular health, aiming to prevent or reduce the progression of heart disease and related conditions. Its platform leverages mobile technology and AI to maximize user engagement and provide personalized insights, making it a valuable tool for both individuals and employers seeking to improve employee wellness and potentially reduce healthcare costs (helloheart, healthselect).

Targeting a broad market that includes individual consumers, employers, and healthcare providers, Hello Heart emphasizes its mission to change the way people care for their hearts by providing accessible, engaging, and effective cardiovascular health management solutions. The company’s value proposition centers on improving health outcomes through innovative digital therapeutics and proactive health monitoring, aligning with current trends in preventive healthcare and digital health innovation (linkedin).

Hello Heart

Hello Heart Weekly Intel Updates

Receive weekly intel updates about Hello Heart straight to your inbox.

Competitors

Hello Heart Competitors

Vida Health is a prominent competitor to Hello Heart, specializing in chronic condition management and medical weight loss. It differentiates itself through personalized, holistic health programs that integrate mental health support, making it appealing for users seeking comprehensive care. Vida Health's market positioning focuses on personalized digital health coaching, and it is often compared to Hello Heart for its tailored approach and broader health management features (CB Insights, Shortlister). In terms of features, Vida offers extensive coaching and mental health integration, which may give it an edge over Hello Heart's blood pressure and cardiovascular focus. Pricing details are less transparent but generally competitive within the digital health coaching space, with a growing market share driven by its personalized approach.

Omada Health is another key player, known for its focus on chronic disease prevention and management, including diabetes and hypertension. Omada emphasizes behavioral science and data-driven interventions, positioning itself as a scalable, evidence-based solution. Compared to Hello Heart, Omada offers a broader range of condition-specific programs, with a strong emphasis on long-term lifestyle change. Its market share is expanding as healthcare providers increasingly adopt digital therapeutics, and its features include personalized coaching, remote monitoring, and digital therapeutics, often at a similar or slightly higher price point (CB Insights). Omada's comprehensive approach and proven clinical outcomes give it a competitive edge in the digital health market.

Apple Health and Fitbit are indirect competitors, primarily through their health tracking platforms and integration with wearable devices. Apple Health offers a broad ecosystem that includes blood pressure monitoring, activity tracking, and health data management, positioning itself as a comprehensive health hub. Fitbit, owned by Google, provides extensive activity and health tracking features, with a focus on fitness and wellness. While these platforms lack the specialized clinical management features of Hello Heart, their large user bases and integration with wearable tech make them significant competitors in the digital health space. Their market positioning is more consumer-focused, often at a lower price point or free, which impacts market share dynamics (TrustRadius).

Vora is an emerging competitor with a focus on digital health management, offering personalized health insights and coaching. Its differentiation lies in advanced AI-driven analytics and user engagement strategies, aiming to provide highly tailored health interventions. Compared to Hello Heart, Vora emphasizes data-driven personalization and user engagement, potentially offering more dynamic and adaptive health management solutions. While its market share is still developing, Vora's innovative approach positions it as a notable contender in the evolving digital health landscape (AskVora). Overall, these competitors vary from specialized condition management to broad health tracking, each leveraging unique features and market strategies to capture share from Hello Heart.

Product & Pricing

Hello Heart Product and Pricing Intelligence

As of April 2026, Hello Heart offers a range of pricing plans tailored for individuals, employers, and health plans, with specific features and tiers. The platform provides both free and paid features, with the paid plans typically including comprehensive heart health monitoring tools such as blood pressure and cholesterol tracking, personalized health insights, and medication management (PulseSignal).

For individual users, detailed pricing plans include various tiers, though specific costs are not explicitly listed in the available sources. However, the platform emphasizes its value through health management features that can lead to cost savings and improved health outcomes (Hello Heart).

In the context of employer and health plan solutions, Hello Heart has introduced programs with performance guarantees aimed at reducing healthcare costs and improving cardiovascular health outcomes. These enterprise solutions often involve customized pricing based on the scope of services and the number of users (Hello Heart). Recent updates highlight a focus on integrating symptom tracking and medication adherence tools to enhance user engagement and health management (Hello Heart Blog).

Overall, while specific current prices are not detailed in the search results, Hello Heart's offerings include free basic monitoring features and paid plans with advanced tools, tailored for both individual consumers and larger organizations, with recent enhancements aimed at improving health outcomes and cost efficiency.

Ad Campaigns

Hello Heart Ad Campaigns

Hello Heart is currently running 66 ads across Google, LinkedIn — 6 on Google and 60 on LinkedIn. Explore Hello Heart's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.

See of Hello Heart's ads

View ads

Hiring & Layoffs

Hello Heart Hiring and Layoffs

As of April 2026, Hello Heart continues to demonstrate a strong focus on growth and innovation, actively hiring for multiple roles across various departments such as business development, corporate strategy, customer success, data, and finance (Hello Heart Careers). The company's recent job postings suggest a strategic emphasis on expanding its team to support its mission of improving heart health and integrating advanced technologies like AI, as indicated in their recent resource on CMS trends (Hello Heart CMS Trends).

While there is no publicly available information indicating layoffs at Hello Heart, their ongoing recruitment efforts and new leadership roles, such as the Director of Health Plan Growth, imply a proactive approach to scaling operations and strengthening market presence (Hello Heart Director Role). This hiring pattern signals a company strategy focused on innovation, expanding healthcare solutions, and deepening partnerships in the health tech space. Overall, Hello Heart’s recruitment trends reflect a company committed to growth and technological advancement in the digital health sector.

Leadership

Hello Heart Management and Leadership Team

The leadership team at Hello Heart includes key executives such as Maayan Cohen, who serves as CEO, and Jesús Bermúdez, the Chief Growth Officer. The team also features Michal Gutman as CTO & CISO, Sue Giordano as Chief Client Officer, Valarie Arismendez as SVP of People, and Ziv Meltzer, a Co-Founder and Board Member (theorg.com).

Recent leadership changes include the appointment of David Wood as General Counsel in January 2026, bringing extensive legal and regulatory expertise from his previous role at Hinge Health. His addition is part of the company's strategic growth during a period of rapid expansion (helloheart.com).

Regarding the board, Ziv Meltzer remains a notable member, and there is no publicly available information indicating recent changes to the board composition. The company continues to focus on scaling its executive team with notable hires like David Wood to support its mission of digital heart health innovation (helloheart.com).

Financials

Hello Heart Financial Performance, Fundraising, M&A

As of 2026, Hello Heart has demonstrated significant financial growth and active fundraising efforts. The company notably closed a $70 million Series D funding round in 2022, which was driven by increased demand for digital heart health solutions among employers (Business Wire). This funding round highlights its strong investor confidence and financial health.

Regarding revenue figures, detailed and recent financial statements are not publicly available, but sources indicate ongoing growth and revenue expansion, supported by its increasing market footprint and customer base (Growjo). The company's valuation has likely increased in line with its funding rounds and market demand, although specific valuation figures as of 2026 are not publicly disclosed.

In terms of M&A activity, there are no publicly reported acquisitions involving Hello Heart up to 2026. The company appears to be focused on organic growth, product development, and expanding its market presence rather than pursuing acquisitions. Overall, Hello Heart's financial health seems robust, supported by substantial funding, increasing revenue, and strategic market positioning (PitchBook).

Partnerships

Hello Heart Partnerships, Clients and Vendors

Hello Heart has established a strong ecosystem of partnerships, enterprise clients, and technology integrations that position it as a leader in digital cardiovascular health. Notably, the company collaborates with major organizations such as the American College of Cardiology through a strategic partnership announced in March 2026, emphasizing its focus on advancing digital innovation in preventive heart health (helloheart.com).

Hello Heart's client base includes over 150 Fortune 500 companies and government entities, including prominent employers like 3M, Lenovo, and the State Health Plan of North Carolina, which utilize its digital health solutions (helloheart.com). The company also partners with health plans such as Navitus, integrating seamlessly into their ecosystems to offer digital heart health benefits, thereby expanding its reach within the healthcare industry (helloheart.com), (navitus.com).

Furthermore, Hello Heart is integrated into broader healthcare networks, including the CVS Health Point Solutions Management program and the virtual care platform Amwell, which enhances its technological ecosystem and broadens its service delivery channels (helloheart.com), (fiercehealthcare.com). The company's collaborations focus on evidence-based digital innovations aimed at improving cardiovascular health outcomes.

Events

Hello Heart Event Participations

Hello Heart actively participates in a variety of events, including conferences, trade shows, webinars, and community events. Notably, they host and attend events such as the Women's Heart Health Summit 2026 and Roadshows in various cities like Chicago and Minneapolis, which aim to promote heart health awareness and engagement (Hello Heart Events).

In addition to hosting their own events, Hello Heart has been involved in larger industry conferences such as HLTH 2025, a major health innovation event, and has participated in the 2023 Annual Employee Healthcare Conference, sharing insights on employee health programs (Hello Heart Events; Hello Heart Staff).

Furthermore, they have announced strategic collaborations, such as with the American College of Cardiology, which underscores their active engagement in professional health communities and initiatives (Hello Heart Press). These activities demonstrate Hello Heart's commitment to community involvement and industry leadership in digital heart health solutions.

Frequently Asked Questions

What does Hello Heart's hiring for a Director of Health Plan Growth signal about its go-to-market strategy?

Hello Heart is making a deliberate push into the health plan channel as a distinct revenue stream alongside its employer base. The Director of Health Plan Growth role, combined with active recruitment across business development and corporate strategy, suggests the company is building dedicated sales and relationship infrastructure to capture health plan partners at scale — a logical move given its recent partnership with Navitus and integration into CVS Health's Point Solutions Management program.

What does the $70M Series D in 2022 tell us about Hello Heart's current funding posture, and is another raise likely?

The Series D closed in April 2022, meaning Hello Heart is now four-plus years into deploying that capital with no publicly disclosed subsequent round. Combined with active hiring across finance, data, and corporate strategy as of early 2026, the company appears to be approaching a decision point — either it has reached sustainable unit economics or it is preparing for a Series E. No specific valuation or revenue figure is publicly disclosed, so the trajectory is directionally positive but not yet quantifiable from public data alone.

What does Hello Heart's partnership with the American College of Cardiology mean for its competitive positioning against Omada Health and Vida Health?

The March 2026 ACC collaboration gives Hello Heart a clinical credibility signal that generalist competitors like Vida Health and Omada Health cannot easily replicate in the cardiovascular-specific segment. While Omada has broad chronic-disease programs and Vida integrates mental health, Hello Heart is staking out a defensible niche as the cardiovascular specialist with professional-society endorsement — an asset particularly valuable when selling to health plans and self-insured employers who scrutinize clinical evidence.

What does Hello Heart's appointment of David Wood as General Counsel in January 2026 suggest about where the company is headed operationally or strategically?

Bringing in a General Counsel with regulatory expertise sourced from Hinge Health — itself a late-stage digital health company — typically signals one of three things: preparation for a financing event, anticipation of heightened regulatory scrutiny as the product touches clinical decisions, or groundwork for M&A activity either as acquirer or target. Given that Hello Heart has no publicly disclosed acquisitions to date, the hire most plausibly reflects scaling compliance infrastructure ahead of a financing or exit event, though the material does not confirm which.

With 150-plus Fortune 500 and government clients, is Hello Heart's enterprise concentration a strength or a strategic vulnerability?

It is both. The Fortune 500 and government-entity client roster — including 3M, Lenovo, and the State Health Plan of North Carolina — demonstrates product-market fit at the large-employer segment and provides durable, multi-year contract revenue. The vulnerability is concentration risk: large employers are increasingly consolidating point solutions through benefits platforms and intermediaries like CVS Health, which means Hello Heart's inclusion in CVS's Point Solutions Management program is critical infrastructure for retention but also creates channel dependency.

Hello Heart is hiring simultaneously in business development, customer success, and data — what does that combination suggest about near-term product and revenue priorities?

Concurrent hiring across BD, customer success, and data points to a company trying to expand its book of business while simultaneously reducing churn and deepening product analytics — a pattern consistent with a SaaS business that has established repeatable sales but is under pressure to demonstrate retention and outcomes to renewing employers. The data hiring in particular aligns with Hello Heart's stated push into AI-driven personalization and its focus on performance-guarantee-based pricing for enterprise clients.

What does Hello Heart's Women's Heart Health Summit 2026 and roadshow activity in cities like Chicago and Minneapolis reveal about its demand-generation strategy?

These events are employer-market demand-generation plays, not consumer marketing. Chicago and Minneapolis are major self-insured employer markets with large benefits decision-maker populations, and the Women's Heart Health Summit targets a clinically underserved segment that resonates strongly with HR and benefits buyers. The roadshow format also suggests Hello Heart is investing in direct, face-to-face sales cycles rather than relying solely on broker or health-plan distribution.

How does Hello Heart's integration with Amwell and CVS Health's Point Solutions Management program change the competitive calculus against Apple Health and Fitbit?

The Amwell and CVS integrations move Hello Heart out of direct consumer competition with Apple Health and Fitbit and into the employer-benefits and virtual-care channel, where those consumer platforms have little presence. Apple Health and Fitbit compete on device ecosystems and consumer data; Hello Heart competes on clinical outcomes, employer ROI, and reimbursement-adjacent positioning — different buyer, different decision criteria, and a channel where Hello Heart has structural advantages its consumer competitors lack.

Hello Heart has been founder-led since 2013 with no disclosed acquisitions — does the current leadership composition suggest that will change?

The leadership team has been deliberately professionalized: a Chief Growth Officer, Chief Client Officer, and now a General Counsel from Hinge Health have been added alongside co-founder Ziv Meltzer remaining on the board. This is a classic pre-exit or pre-Series-E executive buildout. No acquisition targets or acquirers are named in available data, but the pattern — seasoned functional leaders added rapidly, legal infrastructure strengthened — is consistent with a company preparing for a significant transaction within a 12-to-24-month window.

What does Hello Heart's performance-guarantee pricing model for enterprise clients mean for its revenue quality relative to competitors?

Performance-guarantee pricing is a double-edged signal: it demonstrates confidence in clinical outcomes and is an effective sales tool against competitors who cannot make the same commitment, but it also creates contingent revenue risk if health outcomes or engagement metrics underperform. Relative to Omada Health, which also uses outcomes-based contracting, Hello Heart's cardiovascular specialization may give it tighter outcome predictability in its core use case — but the model makes revenue forecasting more complex than pure subscription SaaS.

What gap does Hello Heart's Navitus health-plan partnership expose about its previous distribution model?

The Navitus partnership, which integrates Hello Heart into the health plan's member benefits, signals that Hello Heart recognized a gap in its direct-to-employer model: reaching employees at companies that purchase benefits through fully-insured or PBM-administered plans rather than self-insured arrangements. By embedding inside Navitus's ecosystem, Hello Heart accesses a member population it could not efficiently reach through its existing Fortune 500 sales motion, effectively adding a second distribution layer without building a consumer acquisition engine.

How should a corp-dev team interpret Hello Heart's competitive positioning — is it a consolidation target, a platform extender, or a standalone compounder?

Hello Heart looks most like a consolidation target or platform-extension acquisition for a large health plan, PBM, or benefits administration platform. Its cardiovascular-only focus, ACC partnership, Fortune 500 client base, and integration with CVS and Amwell make it an attractive bolt-on for any acquirer wanting a credentialed point solution in cardiometabolic health — the largest cost driver in employer healthcare spending. Standalone compounding is possible if it raises a Series E and expands into adjacent chronic conditions, but the current product scope and distribution partnerships suggest the strategic logic favors acquisition over independence.

Powered by ForesightIQ · Competitive intelligence from digital exhaust